| Literature DB >> 25540073 |
Philippe Nizard, Frédéric Ezan, Dominique Bonnier, Nolwenn Le Meur, Sophie Langouët, Georges Baffet, Yannick Arlot-Bonnemains, Nathalie Théret1.
Abstract
BACKGROUND: Cell proliferation is a hallmark of cancer and depends on complex signaling networks that are chiefly supported by protein kinase activities. Therapeutic strategies have been used to target specific kinases but new methods are required to identify combined targets and improve treatment. Here, we propose a small interfering RNA genetic screen and an integrative approach to identify kinase networks involved in the proliferation of cancer cells.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25540073 PMCID: PMC4367906 DOI: 10.1186/1471-2164-15-1169
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Experimental workflow to identify kinase targets using high-content imaging. (A) Cells were fluorescently labeled for DNA (DAPI staining, blue channel) and for phosphorylated histone H3 (green channel) as indicated above the photographs. Using CellProfiler software, snapshots were split into blue and green channels. For each image a local correction was applied and objects (nucleus and phosphohistone H3-positive cells) were counted. (B) Normalization and Mitotic Index quantification were performed using CellHTS2 free software. The diagram depicts box-plots of the whole experiment.
Figure 2Variation of the mitotic index (MI) in HeLa cells transfected with siRNA targeted against kinases. Illustration of MI variation of kinases for which siRNA significantly induced either an increase (High) or a decrease (Low) in mitotic index compared to the mean MI of cycling cells reported as 5% in the literature (red band).
Lists of protein kinases whose inhibition leads to low and high Mitotic Index
| Low mitotic index | High mitotic index | ||
|---|---|---|---|
| Symbol | Gene description | Symbol | Gene description |
| ACVR1B | Activin A receptor, type IB | AKT3 | V-akt murine thymoma viral oncogene homolog 3 |
| ADRBK2 | Adrenergic, beta, receptor kinase 2 | ALS2CR2 | Amyotrophic lateral sclerosis 2 (juvenile) chromosome region |
| AK2 | Adenylate kinase 2 | BUB1 | BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) |
| ALPK2 | Alpha-kinase 2 | CAMK1 | Calcium/calmodulin-dependent protein kinase I |
| ARAF | V-raf murine sarcoma 3611 viral oncogene homolog | CDC2L1 | Cell division cycle 2-like protein kinase 1 |
| AURKB | Aurora kinase B | CDC7 | Cell division cycle 7 homolog (S. cerevisiae) |
| BRD4 | Bromodomain containing 4 | CDKL4 | Cyclin-dependent kinase-like 4 |
| BTK | Bruton agammaglobulinemia tyrosine kinase | CHKB | choline kinase beta |
| CAMK1D | Calcium/calmodulin-dependent protein kinase ID | CIT | Citron (rho-interacting, serine/threonine kinase 21) |
| CDC42BPG | CDC42 binding protein kinase gamma (DMPK-like) | DAK | Dihydroxyacetone kinase 2 homolog (S. cerevisiae) |
| CDKL3 | Cyclin-dependent kinase-like 3 | DDR2 | Discoidin domain receptor family, member 2 |
| CLK2 | CDC-like kinase 2 | DGKB | Diacylglycerol kinase, beta 90 kDa |
| CRKL | V-crk sarcoma virus CT10 oncogene homolog (avian)-like | EIF2AK2 | Eukaryotic translation initiation factor 2-alpha kinase 2 |
| DCAMKL1 | Doublecortin-like and CAM kinase-like 1 | ETNK2 | Ethanolamine kinase 2 |
| DGKE | Diacylglycerol kinase, epsilon 64 kDa | FGFR1 | Fibroblast growth factor receptor 1 |
| DMPK | Dystrophia myotonica-protein kinase | FGFR4 | Fibroblast growth factor receptor 4 |
| FER | Fer (fps/fes related) tyrosine kinase | GRK1 | G protein-coupled receptor kinase 1 |
| FGFR3 | Fibroblast growth factor receptor 3 | GRK5 | G protein-coupled receptor kinase 5 |
| GSK3A | Glycogen synthase kinase 3 alpha | HIPK2 | Homeodomain interacting protein kinase 2 |
| IRAK3 | Interleukin-1 receptor-associated kinase 3 | IGF1R | Insulin-like growth factor 1 receptor |
| LMTK2 | Lemur tyrosine kinase 2 | IHPK3 | Inositol hexaphosphate kinase 3 |
| LRRK1 | Leucine-rich repeat kinase 1 | LATS2 | LATS, large tumor suppressor, homolog 2 (Drosophila) |
| MAPKAPK3 | Mitogen-activated protein kinase-activated protein kinase 3 | MAP3K14 | Mitogen-activated protein kinase kinase kinase 14 |
| MAPKAPK5 | Mitogen-activated protein kinase-activated protein kinase 5 | MAP3K6 | Mitogen-activated protein kinase kinase kinase 6 |
| MARK1 | MAP/microtubule affinity-regulating kinase 1 | MAPK6 | Mitogen-activated protein kinase 6 |
| MPP3 | Membrane protein, palmitoylated 3 | NAGK | N-acetylglucosamine kinase |
| PDIK1L | PDLIM1 interacting kinase 1 like | NEK10 | NIMA (never in mitosis gene a)- related kinase 10 |
| PDK2 | Pyruvate dehydrogenase kinase, isozyme 2 | PDZD2 | PDZ domain containing 2 |
| PGK2 | Phosphoglycerate kinase 2 | PGK1 | Phosphoglycerate kinase 1 |
| PHKA1 | Phosphorylase kinase, alpha 1 (muscle) | PIM3 | Pim-3 oncogene |
| PHKG2 | Phosphorylase kinase, gamma 2 (testis) | PKMYT1 | Protein kinase, membrane associated tyrosine/threonine 1 |
| PIK3CB | Phosphoinositide-3-kinase, catalytic, beta polypeptide | PLK1 | Polo-like kinase 1 (Drosophila) |
| PRKAA2 | Protein kinase, AMP-activated, alpha 2 catalytic subunit | PLK2 | Polo-like kinase 2 (Drosophila) |
| PRKCE | Protein kinase C, epsilon | PMVK | Phosphomevalonate kinase |
| RIPK2 | Receptor-interacting serine-threonine kinase 2 | PRKAR2B | Protein kinase, cAMP-dependent, regulatory, type II, beta |
| RIPK4 | Receptor-interacting serine-threonine kinase 4 | PRKCB1 | Protein kinase C, beta 1 |
| SPHK2 | sphingosine kinase 2 | PRKD3 | Protein kinase D3 |
| STC1 | Stanniocalcin 1 | PRKDC | Protein kinase, DNA-activated, catalytic polypeptide |
| STK40 | Serine/threonine kinase 40 | PRPS1L1 | Phosphoribosyl pyrophosphate synthetase 1-like 1 |
| TNK1 | Tyrosine kinase, non-receptor, 1 | PSKH1 | Protein serine kinase H1 |
| ULK2 | Unc-51-like kinase 2 (C. elegans) | PXK | PX domain containing serine/threonine kinase |
| SNRK | SNF related kinase | ||
| SRMS | Src-related kinase | ||
| STK17B | Serine/threonine kinase 17b | ||
| STK36 | Serine/threonine kinase 36, fused homolog (Drosophila) | ||
| TNIK | TRAF2 and NCK interacting kinase | ||
| TPK1 | Thiamin pyrophosphokinase 1 | ||
| TRPM7 | Transient receptor potential cation channel, subfamily M, member 7 | ||
| VRK3 | Vaccinia related kinase 3 | ||
| WNK3 | WNK lysine deficient protein kinase 3 | ||
Figure 3Ontology analysis of kinases. (A) Comparative annotations using Fatigo tool of biological processes between kinases for which siRNA induced either an increase (High) or a decrease (Low) in mitotic index (MI). (B) and (C), Directed acyclic graphs from GOTree Machine (GOTM) describing enrichment in cellular component ontology for high-MI (B) and low-MI (C) groups (significant terms are indicated as red box including p value).
Figure 4Protein-protein interaction network for the high-MI group. Nodes are proteins extracted from the PhosphoPOINT database using the name of kinases in the low-MI group as input. Edges represent the relationship between proteins: black edge (1) for interacting proteins; blue edges (2) for interacting proteins as well as phosphoproteins; red edges (3) for substrates and purple edges (4) for substrates as well as interacting phosphoproteins. The insert shows the mitosis regulatory module" that includes the polo-kinase 1 PLK1, the mitotic checkpoint kinase BUB1, the membrane-associated kinase PKMYT1 and the cell cycle division kinase CDC7.
Figure 5Protein-protein interaction network for the low-MI group. Nodes are proteins extracted from the PhosphoPOINT database using the name of kinases in the high-MI group as input. Edges represent the relationship between proteins: black edge (1) for interacting proteins; blue edges (2) for interacting proteins as well as phosphoproteins; red edges (3) for substrates and purple edges (4) for substrates as well as interacting phosphoproteins. The insert shows the EGFR sub-network connected to the FER and CRKL kinases.
Figure 6Ontologic annotation of PPI networks. Comparative annotation of PPIs from the low- and high-MI groups was performed using ClueGO tool as Cytoscape plug-in. Results are expressed as a graph of differential enrichment of molecular function GO terms. The color gradient shows the kinase proportion of each cluster associated with the term (green nodes for the high-MI group and red nodes for the low-MI group). Equal proportions of the two clusters are represented as white nodes.
Figure 7Implication of the FER and CRKL kinases in S-phase replication of HeLa and HuH7 cells. Cells were transfected with FER, CRKL or control siRNAs and analyzed 72 h post-transfection. (A, B), western blot analysis of FER and CRKL expression in HeLa (A) and HuH7 (B). (C), Representative fluorescence microcopy images from HeLa cells (EDU labeling). (D, E), Cell proliferation assay. EDU or methyl-Thymidine incorporations were performed 72 h (a) and 96 h (b) after transfections of HeLa (D) and HuH7 (E) cells. Replication is expressed as the proliferation index (EDU for HeLa cells) and cpm/μg of protein (methyl-3H-Thymidine for HuH7). The statistical significance was (P < 0.05) and (P < 0.001) in HeLa and HuH7 cells, respectively, relative to the control siRNA.